CAR T-Cell therapy for the management of mantle cell lymphoma
Z Huang, VP Chavda, R Bezbaruah, H Dhamne… - Molecular Cancer, 2023 - Springer
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-
cells characterized by translocation, which is typically due to excess expression of Cyclin …
cells characterized by translocation, which is typically due to excess expression of Cyclin …
Modulation of the ubiquitin‐proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors
Regarding the multimechanistic nature of cancers, current chemo‐or radiotherapies often
fail to eradicate disease pathology, and frequent relapses or resistance to therapies occur …
fail to eradicate disease pathology, and frequent relapses or resistance to therapies occur …
A systematic pan-cancer analysis of the gasdermin (GSDM) family of genes and their correlation with prognosis, the tumor microenvironment, and drug sensitivity
Y Zheng, D Yuan, F Zhang, R Tang - Frontiers in Genetics, 2022 - frontiersin.org
Background: Pyroptosis is a programmed cell death process mediated by the gasdermin
(GSDM) protein. However, limited research has been conducted to comprehensively …
(GSDM) protein. However, limited research has been conducted to comprehensively …
Identification of a proteasome-targeting arylsulfonamide with potential for the treatment of Chagas' disease
ML Lima, LB Tulloch, V Corpas-Lopez… - Antimicrobial agents …, 2022 - Am Soc Microbiol
Phenotypic screening identified an arylsulfonamide compound with activity against
Trypanosoma cruzi, the causative agent of Chagas' disease. Comprehensive mode of action …
Trypanosoma cruzi, the causative agent of Chagas' disease. Comprehensive mode of action …
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties
I Cacciatore, H Turkez, A Di Rienzo, M Ciulla… - RSC Medicinal …, 2021 - pubs.rsc.org
Novel boron-based compounds (BBCs) were synthesized and evaluated as potential
candidates for the development of novel drugs against Alzheimer's disease (AD). The …
candidates for the development of novel drugs against Alzheimer's disease (AD). The …
Peptidomimetics and peptide-based blockbuster drugs
J Han, H Konno, T Sato, K Izawa… - Current Organic …, 2021 - benthamdirect.com
Amino acids (AAs) play an important role in the modern health industry. The aim of this
article was to assess that AAs' residues are frequently found in the structures of …
article was to assess that AAs' residues are frequently found in the structures of …
Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomere shortening
L Wang, H Yin, S Huang, S Huang… - Human & …, 2022 - journals.sagepub.com
Bortezomib (BTZ) is a first-generation proteasome inhibitor with anti-tumor properties for
multiple myeloma and mantle cell lymphoma. Increasing evidence has shown that BTZ …
multiple myeloma and mantle cell lymphoma. Increasing evidence has shown that BTZ …
Preparation of novel CaMoO4: Eu3+-MCM-41 nanocomposites and their applications and monitoring as drug release systems
Abstract Bortezomib loaded CaMoO 4: Eu 3+-MCM-41 nanocomposites were prepared and
used in drug release studies. The surface of the synthesized mesoporous MCM-41 was …
used in drug release studies. The surface of the synthesized mesoporous MCM-41 was …
Evodiamine attenuates oxidative stress and ferroptosis by inhibiting the MAPK signaling to improve bortezomib‐induced peripheral neurotoxicity
Y Tang, W Gu, L Cheng - Environmental Toxicology, 2024 - Wiley Online Library
Background Bortezomib (BTZ) is a commonly used antitumor drug, but its peripheral
neuropathy side effect poses a limitation on its dosage. Evodiamine (EVO) exhibits various …
neuropathy side effect poses a limitation on its dosage. Evodiamine (EVO) exhibits various …
Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway
Y Liao, K Hu, W Liu, W Wang, H Qiu… - Basic & Clinical …, 2023 - Wiley Online Library
Hepatocellular carcinoma (HCC) is one of the principle causes of cancer‐associated death
throughout the world. However, the patients with HCC are insensitive to traditional drugs …
throughout the world. However, the patients with HCC are insensitive to traditional drugs …